COMPASS Pathways (NASDAQ:CMPS) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of COMPASS Pathways (NASDAQ:CMPS - Free Report) in a research note issued to investors on Tuesday,Benzinga reports. HC Wainwright currently has a $45.00 price objective on the stock.

Several other equities analysts have also recently commented on CMPS. Canaccord Genuity Group cut their price target on COMPASS Pathways from $23.00 to $15.00 and set a "buy" rating for the company in a report on Friday, February 28th. Stifel Nicolaus started coverage on COMPASS Pathways in a research report on Thursday, February 27th. They issued a "buy" rating and a $11.00 price objective for the company. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $18.00 price objective on shares of COMPASS Pathways in a research report on Wednesday, January 15th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $21.83.

COMPASS Pathways Stock Performance

NASDAQ:CMPS traded down $0.28 during midday trading on Tuesday, reaching $3.74. The stock had a trading volume of 1,089,511 shares, compared to its average volume of 721,420. COMPASS Pathways has a 1-year low of $3.17 and a 1-year high of $11.33. The firm's fifty day simple moving average is $4.04 and its 200-day simple moving average is $5.14. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91. The stock has a market capitalization of $255.89 million, a P/E ratio of -1.70 and a beta of 2.29.

Remove Ads

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.01). On average, equities research analysts forecast that COMPASS Pathways will post -2.33 EPS for the current fiscal year.

Hedge Funds Weigh In On COMPASS Pathways

Hedge funds and other institutional investors have recently modified their holdings of the stock. Polar Asset Management Partners Inc. lifted its position in shares of COMPASS Pathways by 83.3% during the 3rd quarter. Polar Asset Management Partners Inc. now owns 567,600 shares of the company's stock worth $3,576,000 after buying an additional 258,000 shares during the period. Sio Capital Management LLC lifted its position in shares of COMPASS Pathways by 211.7% during the 3rd quarter. Sio Capital Management LLC now owns 914,639 shares of the company's stock worth $5,762,000 after buying an additional 621,222 shares during the period. Walleye Capital LLC bought a new position in shares of COMPASS Pathways during the 3rd quarter worth approximately $2,126,000. Geode Capital Management LLC lifted its position in shares of COMPASS Pathways by 160.3% during the 3rd quarter. Geode Capital Management LLC now owns 42,169 shares of the company's stock worth $266,000 after buying an additional 25,970 shares during the period. Finally, Acuta Capital Partners LLC bought a new position in shares of COMPASS Pathways during the 3rd quarter worth approximately $2,435,000. Institutional investors own 46.19% of the company's stock.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.